24.05.2018 18:00:00
|
VitalConnect Announces Joe Lynch as Chief Marketing Officer
SAN JOSE, Calif., May 24, 2018 /PRNewswire/ -- VitalConnect®, Inc., a leader in wearable biosensor technology for wireless monitoring in hospital and remote patient populations, today announced the addition of chief marketing officer Joe Lynch. Lynch brings nearly three decades of experience, most recently serving as vice president of marketing at Omnicell (NASDAQ: OMCL). He will report to CEO and founder Nersi Nazari.
Lynch will spearhead the launch of the Vista Solution™ platform and VitalPatch® wearable biosensor with health systems nationwide. Together, the Vista Solution and VitalPatch biosensor offer an elegant, best-in-class solution that increases patient mobility and comfort, provides oversight without additional caregiver burden, and enhances patient care.
"As healthcare continues to evolve to better serve patients, our team is working to bring real-time, continuous monitoring to hospitals and home care settings," said Nazari. "Joe brings a proven track record in leading high growth marketing strategies and programs that will shape and enable our commercial success, furthering our commitment to helping clinicians deliver the best patient care."
As an accomplished medical technology business leader, Lynch has led teams that have meaningfully advanced patient care and achieved significant financial results. He brings a rich background in marketing, strategy, product development and sales within the healthcare industry. At Omnicell, he spent nearly 10 years overseeing product launches and marketing programs that contributed to Omnicell's success in revolutionizing the patient medication experience, achieving revenue growth to over $700 million, and being awarded the 2017 Frost & Sullivan Global Smart Hospitals' Pharmacy Automation Company of the Year. Prior to Omnicell, Lynch served in various leadership roles at Abbott Vascular and Guidant Corporation. Lynch received an MBA from The Wharton School, University of Pennsylvania and a BS from University of Colorado, Boulder.
"I'm excited about joining VitalConnect and the opportunity to activate a new standard of patient care and analytics," said Lynch. "The company's breakthrough continuous patient monitoring technologies are beginning to enable the future of affordable healthcare. Now more than ever, providers need partners who can seamlessly extend essential care platforms to the home to provide excellent patient experiences and outcomes."
About VitalConnect, Inc.
VitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect's products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post discharge care, cardiac monitoring and pharmaceutical solutions. For more information: www.vitalconnect.com.
Contact: Whitney Wells
BAM Communications
561-927-7803
whitney@bamcommunications.biz
View original content with multimedia:http://www.prnewswire.com/news-releases/vitalconnect-announces-joe-lynch-as-chief-marketing-officer-300652338.html
SOURCE VitalConnect, Inc.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Omnicell Inc.mehr Nachrichten
22.01.25 |
Erste Schätzungen: Omnicell veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
21.01.25 |
NASDAQ Composite Index-Papier Omnicell-Aktie: So viel Gewinn hätte ein Omnicell-Investment von vor einem Jahr abgeworfen (finanzen.at) | |
14.01.25 |
NASDAQ Composite Index-Wert Omnicell-Aktie: So viel Gewinn hätte ein Omnicell-Investment von vor 10 Jahren abgeworfen (finanzen.at) | |
07.01.25 |
NASDAQ Composite Index-Papier Omnicell-Aktie: So viel hätten Anleger an einem Omnicell-Investment von vor 5 Jahren verloren (finanzen.at) | |
31.12.24 |
NASDAQ Composite Index-Papier Omnicell-Aktie: So viel Verlust hätte ein Investment in Omnicell von vor 3 Jahren bedeutet (finanzen.at) | |
24.12.24 |
Pluszeichen in New York: NASDAQ Composite klettert zum Handelsende (finanzen.at) | |
24.12.24 |
Zuversicht in New York: NASDAQ Composite-Anleger greifen am Nachmittag zu (finanzen.at) | |
24.12.24 |
Freundlicher Handel: NASDAQ Composite-Anleger greifen am Dienstagmittag zu (finanzen.at) |
Analysen zu Omnicell Inc.mehr Analysen
Aktien in diesem Artikel
Omnicell Inc. | 41,20 | 0,49% |